May 18 - 21, 2019
Grand Hyatt Denver
Denver, Colorado, USA
Abstract submission deadline: Wednesday, February 20
Advance registration deadline: Monday, April 8
Saturday, May 18
Sunday, May 19
Monday, May 20
Tuesday, May 21
Saturday, May 18
Welcome and Opening Keynote Session6:30-7:30 p.m.
Welcome RemarksDan Theodorescu, Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California
The epigenetics of cancerPeter A. Jones, Van Andel Research Institute, Grand Rapids, Michigan
Welcome Reception7:30-9:30 p.m.
Sunday, May 19
Continental Breakfast7-8 a.m.
Session 1: Molecular Pathology – Omics, Subtypes, BiomarkersSession Chair: Donna E. Hansel, Oregon Health & Science University, Portland, Oregon8-10 a.m.
Molecular subtypes and liquid biopsies for predicting outcome in bladder cancerLars Dyrskjøt, Aarhus University Hospital, Aarhus, Denmark
Molecular subtypes of bladder cancer: Toward a more granular description of cancer heterogeneityDavid J. McConkey, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, Maryland
Molecular alterations in variant morphologyDonna E. Hansel
The shifting landscape of genomics: Impact on clinical decision makingSeth P. Lerner, Baylor College of Medicine, Houston, Texas
Novel role of ketone body metabolism in acquired gemcitabine resistance*Krizia Rohena-Rivera, Cedars-Sinai Medical Center, Los Angeles, California
Session 2 and Panel Discussion: Urine Molecular DiagnosisSession Chair: Tahlita C.M. Zuiverloon, University of Colorado Denver, Aurora, Colorado10:30 a.m.-12:30 p.m.
A urine assay to triage patients with hematuria for cystoscopyJoep de Jong, Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands
Potential benefits and obstacles to use of urine-based tumor markersYair Lotan, UT Southwestern Medical Center, Dallas, Texas
Incorporating proteomics in bladder cancer molecular diagnosisAntonia Vlahou, Biomedical Research Foundation Academy of Athens, Athens, Greece
Profiling intra-tumoral heterogeneity of bladder cancer subtypes at the single-cell level using machine-learning assisted histopathology*Andries Zijlstra, Vanderbilt University Medical Center, Nashville, Tennessee
Poster Session A / Lunch12:30-3 p.m.
Plenary Session 3: Drivers of Disease – Stem Cells, Molecular Pathways, Tumor MicroenvironmentSession Chair: William Y. Kim, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina3-5 p.m.
Collagen microenvironment in the modulation of local invasion and distal metastasisKeith S. Chan, Baylor College of Medicine, Houston, Texas
Developing rational combination therapy with checkpoint inhibitorsDan Theodorescu,
Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California
Chemotherapy remodels the bladder cancer immune microenvironmentWilliam Y. Kim
Can immunological biomarkers (CD4/CD8/CD25/CD138) predict tumor recurrence and progression in NMIBC?*Melinda Lillesand, Stavanger University Hospital, Stavanger, Norway
Tumor immune microenvironment drives prognostic relevance correlating with bladder cancer subtypes*Markus Eckstein, University Hospital Erlangen, Erlangen, Germany
Monday, May 20
Session 4: Basic and Translational Immuno-OncologySession Chair: Charles G. Drake, Columbia University Medical Center, New York, New York8-10 a.m.
Basic immunological mechanisms of PD-1/PD-L1 blockadeGordon Freeman, Dana-Farber Cancer Institute, Boston, Massachusetts
NK cell activation and inactivation in the tumor microenvironment: Potential for mobilizing NK cells for cancer therapyDavid H. Raulet, UC Berkeley, Berkeley, California
Genetic risk for skin autoimmunity impacts the safety and efficacy of immune checkpoint blockade in urothelial carcinoma^Matthew Albert, insitro, South San Francisco, California
Novel immunotherapy combinations for bladder cancerCharles G. Drake
Plenary Session 5: Models for Discovery
Session Chair: Dan Theodorescu,
Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California10:30 a.m.-12:45 p.m.
Genetic mouse models and organoids: Synergy for functional genomics of bladder cancer genesFrancisco X. Real, Spanish National Cancer Center (CNIO), Madrid, Spain
Patient-derived organoid models of bladder cancerMichael M. Shen, Columbia University College of Physicians & Surgeons, New York, New York
Genetic modeling of bladder cancer in the post-genome eraXue-Ru Wu, NYU School of Medicine, New York, New York
PDX and genetic mouse models for deciphering signaling pathways in bladder cancerFrançois R. Radvanyi, Institut Curie, Paris, France
Similarities in molecular subtypes and subtype immune patterns between naturally-occurring canine and human invasive bladder cancer*Deborah Knapp, Purdue University, West Lafayette, Indiana
Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy*Andrew Hsieh, Fred Hutchinson Cancer Research Center, Seattle, Washington
Free Time (Lunch on Own)12:45-3:30 p.m.
Session 6: Management of Noninvasive DiseaseSession Chair: Peter C. Black, University of British Columbia, Vancouver, BC, Canada3:30-5 p.m.
Intravesical versus systemic therapy: Win, lose, or draw – The future is now for multidisciplinary NMIBC drug developmentNoah M. Hahn, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Intravesical gene therapy for NMIBCColin P.N. Dinney, The University of Texas MD Anderson Center, Houston, Texas
Realizing the potential of targeted therapy in non-muscle invasive bladder cancerPeter C. Black
Poster Session B / Reception5-7:30 p.m.
Tuesday, May 21
Plenary Session 7: Neoadjuvant and Bladder-Sparing Approaches to Invasive DiseaseSession Chair: Jason A. Efstathiou, Massachusetts General Hospital, Boston, Massachusetts8-10 a.m.
Recent clinical advances in trimodality therapy including combining immunotherapy with chemoradiationJason A. Efstathiou
Predictive biomarkers of response to neoadjuvant therapyKent W. Mouw, Dana-Farber Cancer Institute, Boston, Massachusetts
Molecular biomarkers of chemoradiation response in bladder preservation therapyDavid T. Miyamoto, Massachusetts General Hospital, Boston, Massachusetts
Targeting hypoxia and personalizing chemoradiationCatharine West, University of Manchester, Manchester, United Kingdom
Development of a biomarker-based nomogram to predict the pathologic response to neoadjuvant pembrolizumab in muscle-invasive urothelial bladder cancer (MIBC)*Andrea Necchi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Plenary Session 8: Management of Metastatic DiseaseSession Chair: Dean F. Bajorin, Memorial Sloan Kettering Cancer Center, New York, New York10:20 a.m.-12 p.m.
New agents in metastatic urothelial carcinomaAndrea B. Apolo, National Cancer Institute, Bethesda, Maryland
Shaping the future of treatment for metastatic disease: Current standards of care and the clinical trial landscapeDean F. Bajorin
The genomic landscape of metastatic urothelial carcinoma from circulating tumor DNA*Gillian Vandekerkhove, Vancouver Prostate Centre, Vancouver, BC, Canada
Gene expression profiling in wild type and mutant FGFR3 metastatic urothelial cancer treated with combination therapy with vofatamab and pembrolizumab*Woonyoung Choi, Johns Hopkins School of Medicine, Baltimore, Maryland
Closing Remarks / Discussion12 p.m.
*Short talk from proffered abstract^Not eligible for CME credit
Top of page